Alnylam Pharmaceuticals
ALNY
#638
Rank
A$49.42 B
Marketcap
$381.80
Share price
-0.18%
Change (1 day)
70.49%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total assets

Total assets on the balance sheet as of December 2024 : A$6.70 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total assets are A$6.70 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

Alnylam Pharmaceuticals - Total assets on balance sheet (from 2003 to 2024)

Total assets by year

Year Total assets Change
2024-12-31A$6.81 B21.26%
2023-12-31A$5.62 B7.87%
2022-12-31A$5.21 B3.7%
2021-12-31A$5.02 B13.42%
2020-12-31A$4.43 B29.52%
2019-12-31A$3.42 B53.03%
2018-12-31A$2.23 B-12.51%
2017-12-31A$2.55 B45.84%
2016-12-31A$1.75 B-7.95%
2015-12-31A$1.90 B44.28%
2014-12-31A$1.31 B179.8%
2013-12-31A$0.47 B70.4%
2012-12-31A$0.27 B0.63%
2011-12-31A$0.27 B-28.98%
2010-12-31A$0.38 B-27.75%
2009-12-31A$0.53 B-31.84%
2008-12-31A$0.78 B39.2%
2007-12-31A$0.56 B85.51%
2006-12-31A$0.30 B126.52%
2005-12-31A$0.13 B57.34%
2004-12-31A$85.42 M80.48%
2003-12-31A$47.33 M65.52%
2002-12-31A$28.59 M

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
A$1.60 B-76.09%๐Ÿ‡บ๐Ÿ‡ธ USA
A$59.74 B 790.56%๐Ÿ‡บ๐Ÿ‡ธ USA
A$6.27 B-6.53%๐Ÿ‡บ๐Ÿ‡ธ USA
A$3.48 B-48.11%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.14 B-97.79%๐Ÿ‡บ๐Ÿ‡ธ USA
A$161.77 B 2,311.47%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
A$218.64 B 3,159.26%๐Ÿ‡ซ๐Ÿ‡ท France
A$62.22 B 827.50%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel